The CFO's participation adds credibility to the buy signal, but the tiny dollar amount limits conviction. Monitor for additional insider buying in the coming weeks; if the pattern continues, it would strengthen the bullish read. The recent earnings momentum supports a positive fundamental backdrop.
ELAN drugs
ELAN drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 14 $23.67entry
- T+1 · 3mo ago −0.25%α +0.22% · $23.61
- T+5 · 3mo ago +1.27%α +2.64% · $23.97
- T+20 · 2mo ago −2.20%α −0.21% · $23.15
- T+60 · 8d ago +13.39%α +16.44% · $26.84
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three Elanco insiders, including CFO Robert VanHimbergen, purchased a total of $443K in open-market shares over the week following the company's Q2 2026 beat-and-raise earnings report. While the dollar amount is trivial relative to the $11.1B market cap (0.004%), the cluster includes a C-suite executive and follows a strong earnings release that saw a post-earnings sell-off, suggesting insiders view the dip as a buying opportunity.
Key Financial Metrics
Key Facts
- Three insiders bought shares: Director Paul Herendeen ($237K), Director Michael Harrington ($109K), and CFO Robert VanHimbergen ($97K).
- Total open-market purchases: $443K, representing ~0.004% of market cap.
- Purchases occurred 2-9 days after Elanco reported Q2 2026 adjusted EPS of $0.34 (26.5% beat) and raised full-year guidance.
- The stock declined ~16% in the five days following the earnings release, creating a potential entry point for insiders.
Financial Impact
Insider purchases total $443K, negligible relative to $11.1B market cap.
Risk Factors
- Insider purchases are small and may not reflect a strong conviction signal.
- Post-earnings sell-off could continue if market sentiment remains negative despite the beat.
- Animal health sector faces regulatory and competitive headwinds.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ELAN-1786691620351 |
Track record
19 reports on ELAN
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +15.03% at T+5 after the May 19, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $26.68 Now $26.41 −1.01% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $26.78 Now $26.41 −1.38% settles Feb 11
- Nov 6, 202610d ago 8-K Bullish 6/10 Entry $25.74 Now $26.41 +2.60% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $23.68 Now $26.41 +11.53% settles Feb 3
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $25.31 Now $26.41 +4.35% settles Feb 2
- Oct 14, 20264w ago Institutional Cluster Bullish 4/10 Entry $23.54 Now $26.41 +12.19% settles Jan 12
- Sep 11, 20269w ago Press Release Neutral 1/10 Entry $23.17 Now $26.41 +13.98% settles Dec 7
- Aug 21, 202612w ago Insider Cluster Bullish 6/10 Entry $24.42 Now $26.41 +8.15% settles Nov 17
- Aug 21, 202612w ago Insider Cluster Bullish 4/10 Entry $24.42 Now $26.41 +8.15% settles Nov 17
- Aug 18, 202612w ago Insider Cluster Bullish 4/10 Entry $24.50 to $26.50 Now $26.41 +7.80% ▲ +8.16% +9.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers